REPLIGEN CORP — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Repligen reported Q2 2026 revenue of $204M (+12% reported, +13% organic YoY) with adjusted operating income up 55% YoY. The company raised FY26 organic revenue growth guidance to 10.5%–13.5% and adjusted EPS to $2.03–$2.09. Concurrent with earnings, Repligen announced a definitive agreement to acquire BioLife Solutions to strengthen its cell therapy position; the filing provides no acquisition price, payment terms, or deal closing timeline.
Why this rating
Strong organic growth, margin expansion, and guidance raise are positive. BioLife acquisition is significant strategically but lacks material financial detail (price, structure, timing). Combined effect is material for a $6B company but incomplete disclosure limits assessment.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.